Previous studies reported that DPP4 inhibitors could ameliorate high-fat diet-mediated obesity-related glomerulopathy, which may relate to the improved insulin sensitivity and reduced local inflammation through inhibiting macrophage infiltration and IL-6 and TNF-α secretion (95). The gene discussed is DPP4; the disease is obesity due to melanocortin 4 receptor deficiency.